Since the beginning of the AIDS epidemic the treatment of HIV-related non-Hodgkin's
lymphoma (HIV-NHL) has been a challenge. Before the introduction of highly active …

Twenty cases of systemic non-Hodgkin's lymphoma (NHL) in HIV-infected patients were
reviewed over a 10-year-period, divided into Group A, including 13 NHL cases treated …

To determine role of highly active antiretroviral therapy (HAART) and additional factors in
incidence and outcome of patients with AIDS-related non-Hodgkin's lymphomas (NHL) we …

Epidemiological data indicate that the risk of developing non‐Hodgkin lymphoma (NHL) in
HIV positive individuals is related to age and CD4 count (ie degree of immunosuppression) …

The outlook for patients with HIV-associated non-Hodgkin lymphomas (NHLs) has
dramatically improved in the era of highly active antiretroviral therapy (HAART) probably due …

In HIV-positive patients with non-Hodgkin lymphoma (NHL), no benefit of adding rituximab to
chemotherapy was seen in a randomized controlled trial (RCT). We performed a meta …

The incidence of non-Hodgkin's lymphoma (NHL) in individuals infected with human
immunodeficiency virus (HIV) is more than 60 times higher than in matched controls. In the …

PURPOSE: This study investigated the efficacy, toxicity, and pharmacokinetic interactions
resulting from simultaneous combination chemotherapy and highly active antiretroviral …

TO THE EDITOR: Recently Bouè et al1 published the results of a French phase II trial with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in 61 …

Outcomes of HIV-non-Hodgkin lymphoma are improving with the routine use of highly active
antiretroviral therapy and combination chemotherapy. For aggressive HIV-non-Hodgkin …